What is the story about?
What's Happening?
ScaleReady, in partnership with Wilson Wolf Manufacturing, Bio-Techne Corporation, and CellReady, has announced the allocation of nearly $2 million in G-Rex Grants to eight recipients within the California Institute for Regenerative Medicine (CIRM) Manufacturing Network. These grants aim to enhance the capabilities of non-profit academic GMP manufacturing facilities in California, fostering partnerships with industry and non-profit stakeholders. The initiative is part of CIRM's effort to position California as a leading hub for cell and gene therapy (CGT) manufacturing. The grants will support various projects, including the development of novel production systems for immune cell engineering and CAR-T cell therapy production methods. Notable recipients include the University of California, San Diego, City of Hope, Stanford Medicine, and the University of Southern California, among others.
Why It's Important?
The awarding of these grants is significant as it bolsters California's position in the rapidly growing field of cell and gene therapy, which is crucial for advancing medical treatments and therapies. By supporting academic institutions, the initiative aims to accelerate the development of cost-effective and scalable manufacturing platforms for CGT, potentially leading to more accessible and innovative treatments for patients. This move could also enhance California's economic standing by attracting more biotech investments and fostering job creation in the sector. The collaboration between academic and industry stakeholders is expected to drive forward the commercialization of new therapies, benefiting both the healthcare industry and patients in need of advanced treatments.
What's Next?
The recipients of the G-Rex Grants will continue to develop and refine their manufacturing processes, with some projects already entering clinical trials. The initiative is expected to lead to the production of new cell therapies, including CAR-T cell therapies, which are crucial for treating various cancers. ScaleReady's introduction of the LEAN Cell & Gene program, in partnership with Hanson Wade, will further support CGT entities by providing resources to improve manufacturing efficiency and product quality. This ongoing support and development could lead to significant advancements in the field, potentially resulting in new FDA-approved therapies and expanded treatment options for patients.
AI Generated Content
Do you find this article useful?
